Roche and Hansoh expanded their antibody-drug conjugate partnership, agreeing to develop a portfolio of ADCs spanning multiple cancer types. The collaboration adds two preclinical Hansoh ADC programs plus additional programs driven by Roche-identified targets through Hansoh’s ADC platform. The companies did not disclose the specific targets or indications in the announcement. Roche previously licensed a Hansoh ADC program (HS-20110) outside China/Hong Kong/Macau/Taiwan, and the new deal positions Roche to broaden its ADC pipeline while leveraging Hansoh’s discovery and engineering capabilities. For the sector, the agreement signals continued capital concentration in next-generation ADC stacks amid intense competition for differentiated payloads, linker chemistry, and tumor-selectivity strategies. It also reflects persistent bilateral demand for platform partnerships rather than single-asset deals.